Forus secures $150M series C to grow AI-powered medication access platform
Health tech startup Forus banked $150 million in series C funding as it aims to expand its artificial intelligence-powered network to more medical specialties and care settings.
Health technology firm Forus secured $150 million in Series C funding to expand its AI-powered medication access platform. This latest funding round follows a $160 million Series B round in May, bringing the company's total funding to over $300 million. Forus' valuation has now reached $3 billion, tripling from its Series B round.
The startup, formerly known as Tandem, automates prescription workflows using AI, connecting doctors, pharmacies, payers, and biopharma to streamline the path from prescription to patient. Forus handles tedious administrative tasks such as prior authorizations, appeals, financial assistance, and pharmacy routing, making it easier for patients to access the medications they need.
The company now supports patients in 85% of U.S. residential zip codes and has been adopted by more than a third of providers in dermatology, gastroenterology, and autoimmune specialties. Forus aims to put its AI platform in every doctor's office in the country, with CEO and founder Sahir Jaggi emphasizing the company's mission to help people get access to medicine faster, easier, and cheaper.
The new funding will accelerate Forus' expansion into new specialties and care settings, enabling the company to invest in its team, technology, and outreach to more patients and physicians.
Written by urgent.news from Fierce Healthcare's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
